Raymond James Trust N.A. Has $7.08 Million Stock Position in Stryker Co. (NYSE:SYK)


Share on StockTwits

Raymond James Trust N.A. grew its stake in shares of Stryker Co. (NYSE:SYK) by 7.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,883 shares of the medical technology company’s stock after purchasing an additional 1,924 shares during the period. Raymond James Trust N.A.’s holdings in Stryker were worth $7,078,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Slow Capital Inc. acquired a new position in shares of Stryker during the third quarter valued at about $27,000. Fortis Group Advisors LLC acquired a new position in shares of Stryker during the third quarter valued at about $30,000. Demars Financial Group LLC acquired a new stake in shares of Stryker in the 2nd quarter worth about $32,000. Tarbox Family Office Inc. raised its holdings in shares of Stryker by 43.3% in the 3rd quarter. Tarbox Family Office Inc. now owns 192 shares of the medical technology company’s stock worth $40,000 after acquiring an additional 58 shares during the last quarter. Finally, BNC Wealth Management LLC acquired a new stake in shares of Stryker in the 3rd quarter worth about $42,000. Hedge funds and other institutional investors own 71.02% of the company’s stock.

In other Stryker news, CEO Kevin Lobo sold 10,697 shares of the stock in a transaction that occurred on Monday, December 7th. The shares were sold at an average price of $236.28, for a total value of $2,527,487.16. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Timothy J. Scannell sold 5,000 shares of the stock in a transaction that occurred on Monday, November 23rd. The stock was sold at an average price of $232.61, for a total transaction of $1,163,050.00. Over the last ninety days, insiders sold 17,697 shares of company stock valued at $4,168,737. 6.80% of the stock is owned by insiders.

SYK has been the topic of a number of analyst reports. Northland Securities initiated coverage on shares of Stryker in a report on Tuesday, October 6th. They issued a “market perform” rating and a $225.00 target price on the stock. Raymond James upped their target price on shares of Stryker from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. SVB Leerink upped their target price on shares of Stryker from $225.00 to $235.00 and gave the stock an “outperform” rating in a report on Friday, October 30th. BTIG Research upped their target price on shares of Stryker from $234.00 to $252.00 and gave the stock a “buy” rating in a report on Thursday, December 31st. Finally, Canaccord Genuity lowered their target price on shares of Stryker from $240.00 to $234.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $225.92.

SYK traded up $3.99 on Wednesday, hitting $243.20. The company’s stock had a trading volume of 628,445 shares, compared to its average volume of 1,094,967. The company’s 50 day simple moving average is $237.83 and its 200-day simple moving average is $212.03. The firm has a market cap of $91.39 billion, a P/E ratio of 57.77, a price-to-earnings-growth ratio of 3.71 and a beta of 0.78. Stryker Co. has a 12 month low of $124.54 and a 12 month high of $247.44. The company has a quick ratio of 2.12, a current ratio of 2.91 and a debt-to-equity ratio of 0.93.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $2.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.40 by $0.74. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.41 billion. Stryker had a net margin of 11.38% and a return on equity of 20.53%. Stryker’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the firm earned $1.91 EPS. Equities analysts predict that Stryker Co. will post 6.33 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 31st will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, December 30th. This is an increase from Stryker’s previous quarterly dividend of $0.58. This represents a $2.52 annualized dividend and a yield of 1.04%. Stryker’s dividend payout ratio (DPR) is 30.51%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices that are used in various medical specialties.

Read More: Resistance Level

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.